MCID: CHR431
MIFTS: 49

Chronic Venous Insufficiency

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Chronic Venous Insufficiency

MalaCards integrated aliases for Chronic Venous Insufficiency:

Name: Chronic Venous Insufficiency 12 54 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050853
UMLS 71 C1306557

Summaries for Chronic Venous Insufficiency

Disease Ontology : 12 A venous insufficiency that is characterized by lower extremity swelling, hyperpigmentation, pruritus and venous ulceration caused by blood pooling in the veins.

MalaCards based summary : Chronic Venous Insufficiency is related to thrombophilia due to thrombin defect and amaurosis fugax. An important gene associated with Chronic Venous Insufficiency is VCAM1 (Vascular Cell Adhesion Molecule 1), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Hesperidin and Rivaroxaban have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and testes, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 74 Chronic venous insufficiency (CVI) is a medical condition in which blood pools in the veins, straining... more...

Related Diseases for Chronic Venous Insufficiency

Diseases in the Venous Insufficiency family:

Chronic Venous Insufficiency

Diseases related to Chronic Venous Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 thrombophilia due to thrombin defect 31.1 SERPINE1 PLAT F2
2 amaurosis fugax 30.4 SERPINE1 MMP9
3 lipodermatosclerosis 30.1 VEGFA TIMP2 PLAT MMP1
4 hemorrhoid 30.1 MMP9 F2 CRP
5 thrombophilia 30.1 SERPINE1 SELP PLAT F2
6 arteriosclerosis obliterans 30.0 VCAM1 SELP ICAM1
7 post-thrombotic syndrome 30.0 VCAM1 SERPINE1 SELP PLAT ICAM1 F2
8 homocysteinemia 29.9 VCAM1 SERPINE1 F2 CRP
9 pulmonary embolism 29.9 SERPINE1 PLAT F2 CRP
10 relapsing-remitting multiple sclerosis 29.9 TIMP1 MMP9 ITGA4 ICAM1
11 thrombosis 29.6 VCAM1 SERPINE1 SELP PLAT F2
12 pyoderma 29.5 MMP9 MMP1 CRP
13 skin disease 29.5 SELL MMP1 ITGAL ICAM1 CRP
14 arteries, anomalies of 29.4 VEGFA VCAM1 SERPINE1 ICAM1 CRP
15 peripheral artery disease 29.4 VEGFA VCAM1 SELP ICAM1 CRP
16 dermatitis, atopic 29.3 VCAM1 TIMP1 SELP SELL ITGAM ICAM1
17 varicose veins 29.2 VEGFA TIMP2 TIMP1 PLAT MMP9 MMP1
18 proteasome-associated autoinflammatory syndrome 1 29.2 VCAM1 SELP SELL MMP9 ICAM1 CRP
19 localized scleroderma 29.2 VCAM1 TGFB1 MMP1
20 primary progressive multiple sclerosis 29.2 VCAM1 TIMP1 SELL MMP9 ITGAL ITGA4
21 thrombophlebitis 29.1 TGFB1 SERPINE1 SELP PLAT F2 CRP
22 vasculitis 29.1 VCAM1 SELP SELL ITGAM ITGA4 ICAM1
23 chronic ulcer of skin 29.0 VEGFA TIMP2 MMP9 MMP1 CRP
24 vein disease 28.9 VEGFA SERPINE1 SELP PLAT ICAM1 F2
25 body mass index quantitative trait locus 11 28.9 VEGFA VCAM1 SERPINE1 SELL ICAM1 CRP
26 peripheral vascular disease 28.6 VEGFA VCAM1 TIMP1 SERPINE1 SELP PLAT
27 arteriosclerosis 28.5 VCAM1 TIMP1 SERPINE1 SELP MMP9 ITGAL
28 cerebrovascular disease 27.9 VCAM1 SERPINE1 SELP SELL PLAT MMP9
29 venous insufficiency 27.8 VEGFA VCAM1 TIMP2 TIMP1 SERPINE1 SELP
30 vascular disease 27.1 VEGFA VCAM1 TIMP1 TGFB1 SERPINE1 SELP
31 diabetes mellitus 26.3 VEGFA VCAM1 TGFB1 SERPINE1 SELP SELL
32 autoimmune inner ear disease 10.5 TIMP1 MMP9
33 fibrinolytic defect 10.5 SERPINE1 PLAT
34 central serous chorioretinopathy 10.4 SERPINE1 PLAT
35 dowling-degos disease 1 10.4
36 dermatitis 10.4
37 toxicodendron dermatitis 10.4 SELL ICAM1
38 plasminogen activator inhibitor-1 deficiency 10.4 SERPINE1 PLAT
39 autoimmune enteropathy 10.4 ITGAL ICAM1
40 progressive multifocal leukoencephalopathy 10.4 VCAM1 ITGAL ITGA4
41 inflammatory bowel disease 14 10.4 TIMP1 SERPINE1 ICAM1
42 dic in newborn 10.4 SERPINE1 F2
43 myocardial infarction 2 10.3 PLAT MMP9
44 shwartzman phenomenon 10.3 VCAM1 ITGAM ICAM1
45 platelet aggregation, spontaneous 10.3 SELP PLAT
46 pyridoxine deficiency anemia 10.3 VCAM1 F2
47 crescentic glomerulonephritis 10.3 VCAM1 SERPINE1 ICAM1
48 livedoid vasculitis 10.3 SERPINE1 F2
49 arthus reaction 10.3 SELP SELL ICAM1
50 idiopathic eosinophilic pneumonia 10.3 SELL ITGAM ITGAL ITGA4

Graphical network of the top 20 diseases related to Chronic Venous Insufficiency:



Diseases related to Chronic Venous Insufficiency

Symptoms & Phenotypes for Chronic Venous Insufficiency

MGI Mouse Phenotypes related to Chronic Venous Insufficiency:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 CRP F2 ICAM1 ITGA4 MMP12 MMP9
2 hematopoietic system MP:0005397 10.39 F2 ICAM1 ITGA4 ITGAL ITGAM MMP12
3 homeostasis/metabolism MP:0005376 10.39 CRP F2 ICAM1 ITGAL ITGAM MMP1
4 immune system MP:0005387 10.38 CRP F2 ICAM1 ITGA4 ITGAL ITGAM
5 cellular MP:0005384 10.31 F2 ICAM1 ITGA4 ITGAL ITGAM MMP9
6 growth/size/body region MP:0005378 10.26 F2 ICAM1 MMP9 PLAT SELL SELP
7 mortality/aging MP:0010768 10.13 F2 ICAM1 ITGA4 MMP9 PLAT SELL
8 integument MP:0010771 10.07 F2 ICAM1 MMP12 MMP9 PLAT SELL
9 neoplasm MP:0002006 9.91 ICAM1 ITGAL MMP1 MMP9 SELL SERPINE1
10 nervous system MP:0003631 9.9 F2 ICAM1 ITGAM MMP12 MMP9 PLAT
11 reproductive system MP:0005389 9.61 F2 MMP12 MMP9 PLAT SELL TGFB1
12 respiratory system MP:0005388 9.36 F2 MMP12 MMP9 PLAT SELL SELP

Drugs & Therapeutics for Chronic Venous Insufficiency

Drugs for Chronic Venous Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hesperidin Approved, Investigational Phase 4 520-26-3 53477767
2
Rivaroxaban Approved Phase 4 366789-02-8
3
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
4
Coumarin Experimental Phase 4 91-64-5 323
5
Troxerutin Investigational Phase 4 7085-55-4 5486699
6 Salicylates Phase 4
7 Heparinoids Phase 4
8 Hemostatics Phase 4
9 Aminaftone Phase 4
10 Coagulants Phase 4
11 Anti-Inflammatory Agents Phase 4
12 Antithrombins Phase 4
13 Antithrombin III Phase 4
14 Serine Proteinase Inhibitors Phase 4
15
protease inhibitors Phase 4
16 Factor Xa Inhibitors Phase 4
17 HIV Protease Inhibitors Phase 4
18 Anticoagulants Phase 4
19 Anesthetics Phase 4
20 Fibrinolytic Agents Phase 4
21 Glucuronyl glucosamine glycan sulfate Phase 4
22 Hypolipidemic Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Hypoglycemic Agents Phase 4
25 Antimetabolites Phase 4
26
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
27
Polidocanol Approved Phase 3 9002-92-0
28
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
29
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
30
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
31
Dalteparin Approved Phase 3 9005-49-6
32
tannic acid Approved Phase 3 1401-55-4
33
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
34
Becaplermin Approved, Investigational Phase 3 165101-51-9
35 Tin Fluorides Phase 3
36 calcium heparin Phase 3
37 Calcium, Dietary Phase 3
38 Heparin, Low-Molecular-Weight Phase 3
39 Mitogens Phase 3
40 Carboxymethylcellulose Sodium Phase 3
41 Angiogenesis Inducing Agents Phase 3
42
Calcium Nutraceutical Phase 3 7440-70-2 271
43 Grape Approved Phase 2
44
Timolol Approved Phase 2 26839-75-8 5478 33624
45
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
46
Quercetin Experimental, Investigational Phase 2 117-39-5 5280343
47
Horse chestnut Experimental Phase 2
48 Pharmaceutical Solutions Phase 2
49 Anti-Bacterial Agents Phase 1, Phase 2
50 Sclerosing Solutions Phase 2

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Evaluate the Efficacy and Safety of Esarin Gel in the Treatment of Chronic Venous Insufficiency or Varicose Vein Combine With Superficial Vein Thrombophlebitis in Outpatient Completed NCT02346058 Phase 4 Esarin Gel
2 A 6-week, Open, Multicentre Safety Trial to Evaluate the Tolerability Profile of Antistax® Film Coated Tablets (Extr. Vitis Viniferae Siccum), 360 mg/Day Per os, in Male and Female Patients Suffering From Chronic Venous Insufficiency Completed NCT02184234 Phase 4 Antistax film coated tablets
3 Multicenter, Prospective, Randomized, Double-Blind Study to Assess the Therapeutic Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency Completed NCT00835822 Phase 4 Venocur Triplex®;placebo
4 Gliding Aids for Medical Compression Stockings - Practicability in Elderly Patients With Chronic Venous Insufficiency Completed NCT01432795 Phase 4
5 Evaluation of Efficacy and Safety of the Fixed-dose Combination of Coumarin and Troxerutin (Venalot®) Versus Placebo in the Symptomatic Treatment of Chronic Venous Insufficiency - VENACT Completed NCT01848210 Phase 4 Coumarin/troxerutin;Placebo
6 Randomized Double-blind Trial Between Clinical and Endovascular Treatment in Patients With Advanced Chronic Venous Insufficiency and Iliac Venous Obstruction Completed NCT02149212 Phase 4 Phlebotonic
7 Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein: A Prospective Randomized Trial Completed NCT02236338 Phase 4
8 Clinical Non-inferiority Study Between Diosmin 600 mg Tablets and Diosmin 900 mg + Hesperidin 100 mg Tablets in Symptomatic Chronic Venous Insufficiency After 6 Months of Treatment: Single-blind, Randomized, Parallel Group Study Completed NCT03471910 Phase 4 Diosmin;Diosmin / Hesperidin
9 The Efficacy of Rivaroxaban With Diosmin in the Long-term Treatment of Acute Proximal Deep Vein Thrombosis Completed NCT03413618 Phase 4 Rivaroxaban;Diosmin
10 The Effect of Neuromuscular Electrical Therapy on Pain in Patients With Venous Ulcers: a Controlled Clinical Trial Completed NCT01372020 Phase 4
11 Study of Antiinflammatory Effects of Detralex (Daflon) in Patients With Chronic Venous Disease Completed NCT01654016 Phase 4 Detralex
12 Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein: A Prospective Randomized Trial Terminated NCT02248740 Phase 4
13 Prospective Evaluation of the Quality of Life of Patients With Post-thrombotic Syndrome Who Receive Compression Therapy and Sulodexide — SQUARES Study Terminated NCT02512601 Phase 4 Sulodexide
14 A Clinical Multicenter, Phase III, Prospective, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon Unknown status NCT01477281 Phase 3 Daflon;Venaflon (Diosmin and Hesperidin)
15 Study Clinical, Multicenter,Phase III,Prospective,Randomized,Comparative Double Blind/Double-dummy to Assess the Efficacy and Tolerability of the Use of Varicell in Reducing the Symptoms Caused by Chronic Venous Insufficiency and Hemorrhoidal Syndrome When Compared With Daflon Unknown status NCT01321619 Phase 3 Daflon;Varicell placebo
16 A Comparative Study to Assess the Efficacy and Safety of Endolex Forte vs Diosmin and Hesperidin in Reducing the symptomatoLogy of Patients With ChronIc VeNous Insufficiency Between Functional Classes CEAP 1-4, During a Period of 6 Months Unknown status NCT02927483 Phase 3
17 Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI) Unknown status NCT01110512 Phase 3 Flavonid;Daflon
18 Randomized Single Center Comparative Study of the Treatment of Insufficient Greater Saphenous Vein: Surgery vs Ultrasound Guided Sclerotherapy With Foam and Endovenous Laser Therapy Unknown status NCT00529672 Phase 3
19 A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency. Completed NCT00292435 Phase 3 Read vine leaf extract (AS 195)
20 A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency Completed NCT02191254 Phase 3 Antistax®;Placebo
21 A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 720 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency Completed NCT00855179 Phase 3 Red vine leaf extract (AS 195);Placebo
22 Prospective, Randomized and Explorative Controlled Study About Influences of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Insufficiency Completed NCT00196443 Phase 2, Phase 3
23 Crenobalneotherapy in the Treatment of Chronic Venous Insufficiency. A Randomized Clinical Trial. Completed NCT01956318 Phase 3
24 Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema. International, Multicentric, Randomised, Controlled, Double Blind Study, in Two Parallel Groups v0322 bc Versus Placebo Completed NCT01402921 Phase 3
25 Evaluation of the Efficacy of Spa Treatment for Prevention of Leg Ulcers in Advanced Chronic Venous Insufficiency. Completed NCT00838500 Phase 3 Immediate spa treatment;Late spa treatment
26 Deep Venous Thrombosis. Long-Term Results After Treatment With Either Low-Molecular -Weight Heparin or Unfractionated Heparin. Examinations of the Venous System. Completed NCT00628576 Phase 3 unfractionated heparin;Tinzaparin (Leo)
27 Double Blind Randomized Controlled Trial of Recombinant Human Platelet Derived Growth Factor-BB Gel (Regranex Gel®) Versus Hydrogel (Duoderm Hydrogel®) for Healing of MARTORELL's Hypertensive Leg Ulcers. ERAN Trial. Completed NCT00970697 Phase 3 becaplermin gel;Duoderm Hydrogel™
28 The MUFFIN-PTS Trial: Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome Not yet recruiting NCT03833024 Phase 3 Micronized Purified Flavonoid Fraction;Placebo
29 Efficacy of Autologous Platelet-Rich Plasma in the Treatment of Vascular Ulcers in Primary Care: Clinical Trial Phase III Withdrawn NCT02213952 Phase 3 Platelet-Rich Plasma
30 Clinical Evaluation of the Safety and Effectiveness of Topical Autologous Platelet Gel (APG) for the Treatment of Lower Extremity Chronic Venous Insufficiency Ulcers. A Multicenter, Randomized, Controlled Clinical Trial Withdrawn NCT00273234 Phase 3
31 A Prospective Double Blind Randomized Controlled Trial Of Electrocoagulation Versus Radiofrequency Treatment Of The Great Saphenous Vein In Patients With Varicose Veins. Unknown status NCT02139085 Phase 2
32 NON-HEALING ULCERS WITHOUT CRITICAL LIMB ISCHEMIA (NEWLI-Trial): A Single Center Pilot Trial on the Efficacy of an Endovascular Approach for Treatment of Non-healing Lower Limb Ulcers in Patients Presenting With a Mild to Moderate Peripheral Artery Disease Unknown status NCT01666093 Phase 2
33 A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patients Suffering From Chronic Venous Insufficiency Completed NCT02191163 Phase 2 Antistax®;Placebo
34 The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study Completed NCT02191280 Phase 2 Antistax®, low dose;Antistax®, high dose;Placebo
35 Physical Conditioning in Management of Chronic Venous Insufficiency Completed NCT00013273 Phase 2
36 A Randomized, Parallel Group, Controlled Study to Assess the Efficacy and Safety of NMBM in the Treatment of Subjects With a Post-cellulitis and Venous Leg Ulcer Completed NCT01770509 Phase 1, Phase 2
37 The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 on the Quality of Life in Females With Chronic Venous Insufficiency Completed NCT02498327 Phase 2
38 Topical Timolol Benefit in Venous Ulcers Completed NCT02422017 Phase 2 Timolol
39 Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers Compared to Moist Wound Care in a Primary Care Setting Completed NCT01817218 Phase 1, Phase 2 Platelet Rich Plasma
40 The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 in the Treatment of Symptoms Associated With Chronic Venous Insufficiency Completed NCT02483962 Phase 2
41 An Open Label Multicenter Safety Study of the Varisolve® Procedure for the Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt Completed NCT00442364 Phase 2 Polidocanol (1%) Microfoam (Varisolve)
42 Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial. Recruiting NCT03154619 Phase 2 0.1% TR 987;Placebo gel
43 Double Blind Randomized Clinical Trial Comparing Pycnogenol Versus Placebo for Pigmentation Prevention After Treatment With Varicose Veins With Foam Sclerotherapy Not yet recruiting NCT04203043 Phase 2 Pycnogenol Oral Product
44 A Phase 1a, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Normal Volunteers Given Punch Skin Biopsies Unknown status NCT00916292 Phase 1 FGF-1 141;FGF-1 141
45 Study on the Effect of Kinesio Taping on Bioelectrical Activity of Gastrocnemius Muscles and Range of Ankle Motion in Post-menopausal Women With Chronic Venous Insufficiency Completed NCT01501188 Phase 1
46 Phase I Open-label, First-in-human Study to Evaluate Feasibility and Safety of Tissue Engineered Veins in Patients With Chronic Venous Insufficiency Not yet recruiting NCT03784131 Phase 1 P-TEV
47 The Clinical Research of Surgery on Primary Chronic Venous Insufficiency Unknown status NCT00931424
48 Venous Pressure Measurement of the Great Saphenous Vein Using Controlled Compression Ultrasound in Healthy Persons and Patients With Chronic Venous Disease as a New Non Invasive Method for Investigation of the Pathophysiology in Primary Varicose Veins Unknown status NCT01000909
49 Safety and Primary Efficacy of the External Synchronized Vein Valve (ESVV) in Treatment of Chronic Venous Insufficiency (CVI) Sequel - A Pilot Study Unknown status NCT01346553
50 Prospective, Single-arm, Single Center, Pilot Study of Vascular Ultrasound Imaging Used as an Adjunct to Intravascular Ultrasound for Diagnosing Iliac Vein Obstruction Unknown status NCT02240914

Search NIH Clinical Center for Chronic Venous Insufficiency

Genetic Tests for Chronic Venous Insufficiency

Anatomical Context for Chronic Venous Insufficiency

MalaCards organs/tissues related to Chronic Venous Insufficiency:

40
Skin, Endothelial, Testes, Liver, Heart, Bone, Monocytes

Publications for Chronic Venous Insufficiency

Articles related to Chronic Venous Insufficiency:

(show top 50) (show all 2646)
# Title Authors PMID Year
1
Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: linkage with varicosis. 61 54
15191401 2004
2
[Cytochromes P450, vascular tone varicosis]. 61 54
12843956 2003
3
[Changes in VCAM-1 cell adhesion molecule after phlebologic thermal care in chronic venous insufficiency of the lower limbs]. 54 61
11917667 2001
4
Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency. 54 61
10086854 1999
5
Expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectin and their ligands VLA-4 and LFA-1 in chronic venous leg ulcers. 61 54
8609252 1996
6
Contralateral limb improvement after unilateral iliac vein stenting argues against simultaneous bilateral stenting. 61
32381472 2020
7
Concomitant chronic venous insufficiency in patients with peripheral artery disease: insights from MR angiography. 61
32100090 2020
8
Catheter-directed foam sclerotherapy, an alternative to ultrasound-guided foam sclerotherapy for varicose vein treatment: A systematic review and meta-analysis. 61
31918640 2020
9
Effect of obesity on chronic venous insufficiency treatment outcomes. 61
32335333 2020
10
Treatment of chronic venous insufficiency in Latin America. 61
32234293 2020
11
Assessment and grading of pigmentation in chronic venous insufficiency. 61
31699007 2020
12
Repurposing the systemic venous return model for conceptualisation of chronic venous insufficiency and its management. 61
32525447 2020
13
The intravascular ultrasound morphometry of iliac veins in subjects without severe chronic venous insufficiency and its implications for treatment indications and stent size selection. 61
31645193 2020
14
Diagnosis and Treatment of Postthrombotic Syndrome. 61
32455461 2020
15
Clinical outcome of short term compression following sclerotherapy of teleangiectatic varicose veins. 61
32502730 2020
16
Hybrid Treatment Combining Lymphaticovenous Anastomoses and the Oriental Herbal Medicine Bofutsushosan for Obesity-Associated Lower Leg Elephantiasis Nostras Verrucosa: A Case Report. 61
32519905 2020
17
Correction to: Sulodexide in the Treatment of Chronic Venous Insufficiency: Results of the All-Russian Multicenter ACVEDUCT Program. 61
32424806 2020
18
Open-label, randomised, multicentre crossover trial assessing two-layer compression bandaging for chronic venous insufficiency: results of the APRICOT trial. 61
32501761 2020
19
Comparison of Unilateral vs Bilateral and Staged Bilateral vs Concurrent Bilateral Truncal Endovenous Ablation in the Vascular Quality Initiative. 61
32470615 2020
20
Supervised exercise protocol for lower limbs in subjects with chronic venous disease: an evaluator-blinded, randomized clinical trial. 61
32430078 2020
21
Early Results (3 months) of an Asian Prospective Multi-Centre VenaSeal™ Real World Post-Market Evaluation to Investigate the Efficacy and Safety of Cyanoacrylate Endovenous Ablation for Varicose Veins (ASVS Study). 61
32387378 2020
22
Randomized Clinical Trial of Radiofrequency Induced Thermotherapy Combined with Transilluminated Powered Phlebectomy versus High Ligation and Stripping for the Treatment of Lower Limb Varicose Veins. 61
32454239 2020
23
Skin disorders indicating peripheral arterial occlusive disease and chronic venous insufficiency in organ transplant recipients. 61
32466875 2020
24
Sulodexide in the Treatment of Chronic Venous Insufficiency: Results of the All-Russian Multicenter ACVEDUCT Program. 61
32112279 2020
25
Chronic Venous Insufficiency As A Predisposing Factor For Basal Cell Carcinoma On Legs. 61
32422291 2020
26
Association between heel-rise test performance and clinical severity of chronic venous insufficiency. 61
32408796 2020
27
Network meta-analysis to compare VenaSeal with other superficial venous therapies for chronic venous insufficiency. 61
32063522 2020
28
Comparison of the Hemodynamic Performance of Two Neuromuscular Electrical Stimulation Devices Applied to the Lower Limb. 61
32392699 2020
29
Antigen removal process preserves function of small diameter venous valved conduits, whereas SDS-decellularization results in significant valvular insufficiency. 61
32151701 2020
30
Therapeutic compression materials and wound dressings for chronic venous insufficiency: A comprehensive review. 61
31339655 2020
31
Recurrence types 3 years after endovenous thermal ablation in insufficient saphenofemoral junctions. 61
32361003 2020
32
Red vine leaf extract (AS 195) can improve some signs and symptoms of chronic venous insufficiency, a systematic review. 61
32314844 2020
33
Comparing the Efficacy of Radiofrequency Ablation Versus Laser Ablation for Chronic Venous Insufficiency in the Lower Extremities: a Vietnamese Report. 61
32577049 2020
34
Venous Ablation. 61
32147125 2020
35
Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study. 61
31899848 2020
36
Hemorrhoidal disease and chronic venous insufficiency: Concomitance or coincidence; results of the CHORUS study (Chronic venous and HemORrhoidal diseases evalUation and Scientific research). 61
31512275 2020
37
Etiology of iliocaval stent thrombosis. 61
31843484 2020
38
Safety of a compression stocking for patients with chronic venous insufficiency (CVI) and peripheral artery disease (PAD). 61
32100962 2020
39
Ultrasonography-guided foam sclerotherapy in patients with small saphenous vein insufficiency. 61
32179038 2020
40
Safe Practice of Y-Site Drug Administration: The Case of Colistin and Parenteral Nutrition. 61
32213881 2020
41
High prevalence of chronic venous disease among health care workers in the United States. 61
32067727 2020
42
The utility of endovenous cyanoacrylate glue ablation for incompetent saphenous veins in the setting of venous leg ulcers. 61
32205130 2020
43
Our experience regarding patients with headache, vomiting, and urinary retention following endothermal ablation of the greater saphenous vein under spinal anesthesia: Gender type, age interval, and procedural risk factors are important. 61
32216537 2020
44
Comparison of different approaches to small saphenous vein reflux treatment: a retrospective study in two centers. 61
32491084 2020
45
Sulodexide Improves Contraction and Decreases Matrix Metalloproteinase-2 and -9 in Veins Under Prolonged Stretch. 61
31738197 2020
46
Clinical response to combination therapy in the treatment of varicose veins. 61
31843482 2020
47
Laser ablation versus mechanochemical ablation in the treatment of primary varicose veins: A randomized clinical trial. 61
31864932 2020
48
Racial disparities in the outcomes of superficial vein treatments for chronic venous insufficiency. 61
32205126 2020
49
Impact of Great Saphenous Vein Foam Sclerotherapy on Quality of Life and Photoplethysmography Findings in Chronic Venous Insufficiency: One-Year Follow-up. 61
31397782 2020
50
Prevention and Management of the Post-Thrombotic Syndrome. 61
32230912 2020

Variations for Chronic Venous Insufficiency

Expression for Chronic Venous Insufficiency

Search GEO for disease gene expression data for Chronic Venous Insufficiency.

Pathways for Chronic Venous Insufficiency

Pathways related to Chronic Venous Insufficiency according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 VEGFA VCAM1 TIMP2 TIMP1 TGFB1 SELL
2
Show member pathways
13.72 VEGFA TIMP2 TIMP1 TGFB3 TGFB1 MMP9
3
Show member pathways
13.58 VEGFA TIMP2 TIMP1 TGFB3 TGFB1 ITGAM
4
Show member pathways
13.42 TIMP2 TIMP1 TGFB3 TGFB1 ITGAM ITGAL
5
Show member pathways
13.4 VEGFA VCAM1 TIMP1 TGFB1 MMP9 MMP1
6
Show member pathways
13.32 VEGFA VCAM1 TGFB3 TGFB1 SERPINE1 MMP9
7
Show member pathways
13.15 VEGFA TIMP1 TGFB3 TGFB1 SERPINE1 SELP
8
Show member pathways
13.12 TIMP2 TIMP1 TGFB3 TGFB1 ITGAM ITGAL
9
Show member pathways
13.08 VCAM1 TIMP2 TIMP1 TGFB3 TGFB1 F2
10
Show member pathways
12.92 VEGFA TGFB3 TGFB1 PLAT MMP9 ITGAM
11 12.89 VEGFA TGFB3 TGFB1 MMP9 MMP1 F2
12
Show member pathways
12.87 TGFB3 TGFB1 ITGAM ITGAL ITGA4
13
Show member pathways
12.87 VEGFA TGFB1 ITGAL ITGA4 ICAM1
14
Show member pathways
12.7 VEGFA VCAM1 MMP9 ITGAM ITGAL ITGA4
15
Show member pathways
12.46 TIMP2 TIMP1 TGFB3 TGFB1 ITGAM ITGAL
16
Show member pathways
12.4 SERPINE1 PLAT ICAM1 F2 CRP
17 12.36 TGFB3 TGFB1 ITGAL ICAM1
18
Show member pathways
12.33 VEGFA TIMP1 SERPINE1 MMP1
19
Show member pathways
12.29 TGFB3 TGFB1 ITGAM ITGA4
20 12.24 VEGFA TGFB3 TGFB1 MMP9 MMP12 MMP1
21
Show member pathways
12.23 VCAM1 ITGAM ITGAL ITGA4 ICAM1
22 12.17 VEGFA VCAM1 PLAT MMP9 ICAM1
23
Show member pathways
12.17 TGFB1 SELP SELL MMP1 ITGAM ITGAL
24 12.16 SERPINE1 PLAT ITGAM F2
25 12.15 VCAM1 SELL ITGAL ITGA4 ICAM1
26 12.15 VCAM1 SELP SELL ITGAM ITGAL ITGA4
27 12.09 VCAM1 SERPINE1 MMP9 ITGA4 ICAM1
28
Show member pathways
12.09 VCAM1 TIMP2 TIMP1 TGFB3 TGFB1 SERPINE1
29 12.08 TGFB1 SELP MMP9 MMP12 ICAM1
30
Show member pathways
11.98 TIMP2 TIMP1 MMP9 MMP12 MMP1
31 11.97 VEGFA VCAM1 TGFB3 TGFB1 SERPINE1 ICAM1
32 11.96 SELP ITGAM ITGAL ICAM1
33 11.95 VCAM1 TGFB3 TGFB1 ITGAM
34 11.92 VEGFA TGFB3 TGFB1 MMP1 ITGAL ICAM1
35 11.91 TIMP2 TIMP1 TGFB3 TGFB1 MMP9
36 11.83 ITGAM ITGAL ITGA4
37 11.79 TIMP2 TIMP1 TGFB3 TGFB1 ITGAM ITGAL
38 11.77 TGFB1 SELL ITGAM
39 11.76 VEGFA MMP9 MMP1
40 11.76 VEGFA TGFB1 PLAT MMP9
41
Show member pathways
11.73 VEGFA VCAM1 MMP9 MMP1 ICAM1
42 11.69 TIMP1 TGFB1 MMP9
43 11.65 TGFB3 TGFB1 SERPINE1
44 11.61 VEGFA VCAM1 TIMP1 TGFB1 MMP9 MMP1
45 11.6 SELP PLAT MMP9 ITGAM ICAM1
46 11.59 VEGFA TGFB1 MMP1
47 11.58 VCAM1 TGFB3 TGFB1 SELP ITGAL ICAM1
48 11.57 VEGFA TGFB1 PLAT
49 11.56 VEGFA TGFB3 TGFB1
50 11.55 VCAM1 ITGAM ITGAL ITGA4 ICAM1

GO Terms for Chronic Venous Insufficiency

Cellular components related to Chronic Venous Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.15 VEGFA TIMP2 TIMP1 TGFB3 TGFB1 SERPINE1
2 extracellular exosome GO:0070062 10.13 VCAM1 TIMP1 SERPINE1 PLAT MMP9 ITGAM
3 external side of plasma membrane GO:0009897 9.88 VCAM1 SELP SELL ITGAM ICAM1 F2
4 extracellular matrix GO:0031012 9.8 VEGFA TIMP2 TIMP1 TGFB1 MMP9 MMP12
5 secretory granule GO:0030141 9.76 VEGFA TGFB3 TGFB1 PLAT
6 collagen-containing extracellular matrix GO:0062023 9.76 TIMP2 TGFB3 TGFB1 SERPINE1 PLAT MMP9
7 platelet alpha granule lumen GO:0031093 9.72 VEGFA TIMP1 TGFB3 TGFB1 SERPINE1
8 cell surface GO:0009986 9.7 VEGFA VCAM1 TIMP2 TGFB3 TGFB1 SELL
9 integrin complex GO:0008305 9.65 ITGAM ITGAL ITGA4
10 extracellular space GO:0005615 9.5 VEGFA VCAM1 TIMP2 TIMP1 TGFB3 TGFB1

Biological processes related to Chronic Venous Insufficiency according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.08 VEGFA TIMP1 TGFB3 TGFB1 F2
2 neutrophil degranulation GO:0043312 10.07 TIMP2 SELL MMP9 ITGAM ITGAL
3 cell adhesion GO:0007155 10.04 VCAM1 SELP SELL ITGAM ITGAL ITGA4
4 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA TGFB1 MMP9 F2
5 aging GO:0007568 9.94 TIMP2 TIMP1 TGFB3 TGFB1
6 regulation of immune response GO:0050776 9.93 VCAM1 SELL ITGAL ITGA4 ICAM1
7 response to hypoxia GO:0001666 9.88 VEGFA TGFB3 TGFB1 PLAT ICAM1
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 VEGFA TGFB1 ICAM1
9 response to organic substance GO:0010033 9.86 TIMP2 TIMP1 TGFB1
10 wound healing GO:0042060 9.85 TIMP1 TGFB3 TGFB1 MMP12
11 positive regulation of protein complex assembly GO:0031334 9.82 VEGFA TGFB1 MMP1
12 extracellular matrix disassembly GO:0022617 9.8 TIMP2 TIMP1 MMP9 MMP12 MMP1
13 platelet degranulation GO:0002576 9.8 VEGFA TIMP1 TGFB3 TGFB1 SERPINE1 SELP
14 cellular response to amyloid-beta GO:1904646 9.79 VCAM1 ITGA4 ICAM1
15 positive regulation of cell division GO:0051781 9.79 VEGFA TGFB3 TGFB1
16 collagen catabolic process GO:0030574 9.78 MMP9 MMP12 MMP1
17 cytokine-mediated signaling pathway GO:0019221 9.76 VEGFA VCAM1 TIMP1 TGFB1 MMP9 MMP1
18 negative regulation of proteolysis GO:0045861 9.74 TIMP2 PLAT F2
19 positive regulation of collagen biosynthetic process GO:0032967 9.73 TGFB3 TGFB1 F2
20 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.73 VCAM1 SELP ITGAL ICAM1
21 fibrinolysis GO:0042730 9.7 SERPINE1 PLAT F2
22 cell activation GO:0001775 9.69 TIMP1 TGFB1
23 positive regulation of superoxide anion generation GO:0032930 9.69 TGFB1 ITGAM CRP
24 positive regulation of vascular permeability GO:0043117 9.68 VEGFA TGFB1
25 negative regulation of fibrinolysis GO:0051918 9.68 SERPINE1 F2
26 salivary gland morphogenesis GO:0007435 9.67 TGFB3 TGFB1
27 negative regulation of metallopeptidase activity GO:1905049 9.67 TIMP2 TIMP1
28 leukocyte tethering or rolling GO:0050901 9.67 VCAM1 SELP SELL ITGA4
29 positive regulation of leukocyte tethering or rolling GO:1903238 9.66 SELP ITGA4
30 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.66 TIMP2 TIMP1
31 response to laminar fluid shear stress GO:0034616 9.65 TGFB3 TGFB1
32 leukocyte cell-cell adhesion GO:0007159 9.65 VCAM1 SELP ITGAL ITGA4 ICAM1
33 ossification involved in bone remodeling GO:0043932 9.64 TGFB3 TGFB1
34 membrane to membrane docking GO:0022614 9.63 VCAM1 ICAM1
35 negative regulation of macrophage cytokine production GO:0010936 9.63 TGFB3 TGFB1
36 positive regulation of leukocyte migration GO:0002687 9.63 VEGFA SELP ITGA4
37 connective tissue replacement involved in inflammatory response wound healing GO:0002248 9.62 TIMP1 TGFB1
38 extracellular matrix organization GO:0030198 9.61 VCAM1 SERPINE1 MMP9 MMP12 MMP1 ITGAM
39 frontal suture morphogenesis GO:0060364 9.6 TGFB3 TGFB1
40 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell GO:0002291 9.59 ITGAL ICAM1
41 regulation of epithelial to mesenchymal transition involved in endocardial cushion formation GO:1905005 9.58 TGFB3 TGFB1
42 cell-cell adhesion in response to extracellular stimulus GO:0140039 9.58 VCAM1 ITGA4
43 leukocyte migration GO:0050900 9.28 TGFB1 SELP SELL MMP1 ITGAM ITGAL

Molecular functions related to Chronic Venous Insufficiency according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.22 TIMP2 TIMP1 SELP SELL MMP9 MMP12
2 peptidase activity GO:0008233 9.95 PLAT MMP9 MMP12 MMP1 F2
3 protein-containing complex binding GO:0044877 9.85 TGFB3 TGFB1 ITGAM ITGAL ICAM1
4 cytokine activity GO:0005125 9.81 VEGFA TIMP1 TGFB3 TGFB1
5 serine-type endopeptidase activity GO:0004252 9.73 PLAT MMP9 MMP1 F2
6 heparin binding GO:0008201 9.71 VEGFA SELP SELL F2
7 protease binding GO:0002020 9.56 TIMP2 TIMP1 SERPINE1 SELL
8 oligosaccharide binding GO:0070492 9.54 SELP SELL
9 type I transforming growth factor beta receptor binding GO:0034713 9.52 TGFB3 TGFB1
10 type II transforming growth factor beta receptor binding GO:0005114 9.49 TGFB3 TGFB1
11 cell adhesion molecule binding GO:0050839 9.46 VCAM1 SELL ITGAL ITGA4
12 glycosphingolipid binding GO:0043208 9.37 SELP SELL
13 growth factor activity GO:0008083 9.35 VEGFA TIMP1 TGFB3 TGFB1 F2
14 type III transforming growth factor beta receptor binding GO:0034714 9.32 TGFB3 TGFB1
15 integrin binding GO:0005178 9.02 VCAM1 TIMP2 ITGAM ITGA4 ICAM1

Sources for Chronic Venous Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....